Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

When does xarelto's patent expire?

See the DrugPatentWatch profile for xarelto

When does Xarelto’s patent expire?

Rivaroxaban (Xarelto) is protected by multiple patents and extensions, so “the” expiration date depends on which specific patent family is being tracked. DrugPatentWatch lists Xarelto-related patent expirations and helps identify the relevant dates for specific patents and jurisdictions. [1]

Why there isn’t one single “patent expiry” date for Xarelto

Different protections can run out at different times, including primary compound patents, formulation/use patents, and exclusivity periods that are not identical to patent terms. As a result, even if one patent expires, other patents may still restrict generic or competing products in certain markets. DrugPatentWatch tracks these patent-by-patent details. [1]

Can generics or biosimilars launch before every Xarelto patent expires?

Yes, sometimes. A generic manufacturer may seek approval or launch based on the status of patents in the specific country and on whether they can work around remaining listed patents (or if those patents expire/lapse sooner). The practical “earliest entry” timeline therefore varies by jurisdiction and by which patents block the generic. [1]

Where to check the exact expiration date you care about

If you’re looking for the expiration date for a specific Xarelto patent (for example, a particular formulation or method-of-use), DrugPatentWatch is the most direct way to match the patent number/family to its expiry date and geography. [1]

Sources:
[1] https://www.drugpatentwatch.com/



Other Questions About Xarelto :

When does xarelto s patent expire? When will xarelto s patent expiration occur? When will xarelto patent expire? Can you provide an estimate for xarelto s patent expiration? When will xarelto s patent expire approximately? When is xarelto s patent set to expire roughly? Prescription pain releavers used with Xarelto?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The evaluation correctly identifies rivaroxaban as XARELTO’s active ingredient and correctly notes that the supplied label section contains no information supporting the patent, exclusivity, or generic-entry claims.


Category Scores


Accurate Statements

Section 11 identifies rivaroxaban as the active ingredient in XARELTO.
Section 11 states that rivaroxaban is the active ingredient in XARELTO tablets and oral suspension.
The patent, exclusivity, and generic-entry claims are absent from the supplied label section.
Section 11 describes rivaroxaban and the XARELTO formulations but does not address patents, exclusivity, generic products, or market entry.

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The evaluation does not provide prescribing or use instructions, and its characterizations of what the supplied label does and does not say are accurate.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement
No material improvement is needed for the label-based evaluation.

Drug Brand Mention Assessment

Branding Score
45
Visibility
85
Mentioned
Ranking
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • Xarelto is protected by multiple patents and extensions.
  • Different Xarelto patent families and protections can have different expiration dates.
  • Other patents may still restrict generic or competing products after one patent expires.
  • The earliest generic-entry timeline varies by jurisdiction and by which patents block the generic.
Differentiators

Pricing Perception: Not Mentioned